Back

Ferric derisomaltose in hospitalised and ambulatory patients with heart failure-insights from the IRONMAN trial

11 May 2024 (15:00 - 15:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 11 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Matthew M Y Lee

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Clinical management strategies of cardiologists in heart failure with reduced ejection fraction
Doctor T. Kivrak (Elazig, TR)
Abstract Slides Video
Presentation thumbnail
Prevalence, characteristics, and phenotype associated with tachycardiomyopathy in a cohort of patients first hospitalized for heart failure with reduced ejection fraction
Mr P. de la Fuente Lopez (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
An intensive nurse-led telemedicine program is effective in achieving optimized up-titration of prognostic drugs in heart failure with reduced ejection fraction patients
Mrs M. Vicente Elcano (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Effect of initiation of sacubitril/valsartan on 24 hours blood pressure in patients with heart failure with reduced ejection fraction
Mr M. Pavelko (Lutsk, UA)
Abstract Slides Video
Presentation thumbnail
TAPSE is a small but big important detail in candidates for heart transplantation
Professor R. Acar (Istanbul, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 11

The Event

Event poster

Heart Failure 2024

11 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Ferric derisomaltose: IRONMAN
thumbnail
Congress Presentation
New IV iron trials
thumbnail
Congress Presentation
Effect of intravenous ferric derisomaltose on outcomes in heart failure with or without ischaemic heart disease in the IRONMAN trial.

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources